« Return to News | Technology Solutions

Almac launches TruSight tumor profiling next-generation sequencing service

Wednesday, September 11, 2013 01:37 PM

Almac has launched a tumor profiling service running Illumina’s next-generation sequencing (NGS) TruSight Tumor panel as part of their biomarker discovery, development and delivery solutions.

Almac, a personalized medicine company with CAP accredited and CLIA certified laboratories, offers TruSight Tumor to complement its current range of RNA, DNA and protein based technologies for biomarker analysis. 

Almac is currently running bespoke diagnostic assays for pharma customers for early phase clinical trial enrichment. The TruSight Tumor panel enables additional profiling of these patient samples to provide Almac’s pharma partners with further information on emerging biomarkers that may also impact drug response.

The TruSight Tumor panel was developed by Illumina for its MiSeq system, allowing targeted DNA sequencing and reporting on the mutation status of 26 genes which are most commonly mutated in solid tumors including lung, colon, ovarian, melanoma and gastric cancers. 

The panel is specifically designed for use with FFPE samples, and enables the highest levels of sensitivity for mutation detection with limited DNA input requirements.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.